Ariella B Hanker Selected Research

Breast Neoplasms (Breast Cancer)

3/2024	PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
1/2024	AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer.
7/2023	Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
2/2023	Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
1/2023	Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
1/2023	Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
1/2023	Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.
1/2021	Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer.
10/2020	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
10/2020	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ariella B Hanker Research Topics

Disease

23	Neoplasms (Cancer) 04/2024 - 01/2008
23	Breast Neoplasms (Breast Cancer) 03/2024 - 01/2008
3	Neoplasm Metastasis (Metastasis) 01/2024 - 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 04/2024
1	Triple Negative Breast Neoplasms 01/2022
1	Bites and Stings (Sting) 01/2022
1	Carcinogenesis 12/2017
1	Pathologic Complete Response 08/2017
1	Disease Progression 01/2017
1	Hypoxia (Hypoxemia) 12/2016

Drug/Important Bio-Agent (IBA)

6	Trastuzumab (Herceptin)FDA Link 02/2023 - 08/2013
6	neratinibIBA 01/2023 - 01/2017
6	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2017
5	Estrogen ReceptorsIBA 03/2024 - 12/2016
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 07/2015
4	Estrogens (Estrogen)FDA Link 01/2021 - 01/2008
3	Biomarkers (Surrogate Marker)IBA 02/2023 - 08/2009
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 12/2016
3	Phosphotransferases (Kinase)IBA 01/2023 - 12/2017
3	ErbB Receptors (EGF Receptor)IBA 12/2017 - 07/2015
2	Phenobarbital (Luminal)FDA Link 04/2024 - 08/2013
2	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 03/2024 - 07/2023
2	Fulvestrant (Faslodex)FDA Link 07/2023 - 01/2023
2	Docetaxel (Taxotere)FDA Link 02/2023 - 01/2023
2	Therapeutic UsesIBA 02/2023 - 01/2023
2	plerixafor FDA Link 02/2023 - 01/2023
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2017
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2021 - 10/2020
2	Mechanistic Target of Rapamycin Complex 1IBA 10/2020 - 02/2020
2	IntegrinsIBA 02/2019 - 01/2017
2	Lapatinib (GW572016)FDA Link 08/2017 - 08/2013
2	Drug CombinationsIBA 08/2017 - 01/2017
2	pertuzumabIBA 01/2017 - 08/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2016 - 01/2016
1	PlasticsIBA 04/2024
1	A-Form DNA (A-DNA)IBA 01/2024
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2024
1	Neurofibromin 1 (Neurofibromin)IBA 01/2023
1	binimetinibIBA 01/2023
1	Dynamins (Dynamin)IBA 01/2023
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	InterferonsIBA 01/2022
1	ChemokinesIBA 01/2022
1	erdafitinibIBA 01/2021
1	Letrozole (Femara)FDA LinkGeneric 01/2021
1	ChromatinIBA 01/2021
1	Small Interfering RNA (siRNA)IBA 01/2021
1	Proline (L-Proline)FDA Link 10/2020
1	Circulating Tumor DNAIBA 10/2020
1	DNA (Deoxyribonucleic Acid)IBA 10/2020
1	palbociclibIBA 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	tyrosine receptor (receptor, tyrosine)IBA 12/2017
1	tributyl phosphate (TBP)IBA 01/2017
1	CollagenIBA 01/2017
1	AntibodiesIBA 01/2017
1	Cell-Free Nucleic AcidsIBA 01/2017
1	NVP-BKM120IBA 01/2017
1	Eukaryotic Initiation Factor-4G (Eukaryotic Initiation Factor 4G)IBA 12/2016
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2016
1	ProteomeIBA 12/2016
1	Messenger RNA (mRNA)IBA 12/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2015
1	human ERBB2 proteinIBA 08/2013
1	ClaudinsIBA 08/2013
1	romidepsin (FK228)FDA Link 08/2009
1	Histone Deacetylase InhibitorsIBA 08/2009
1	Histones (Histone)IBA 08/2009
1	Monomeric GTP-Binding ProteinsIBA 01/2008
1	Guanosine Triphosphate (GTP)IBA 01/2008
1	Growth InhibitorsIBA 01/2008
1	Estrogen Receptor alphaIBA 01/2008

Therapy/Procedure

12	Therapeutics 04/2024 - 08/2013
1	Drug Therapy (Chemotherapy) 10/2015
1	Neoadjuvant Therapy 10/2015